| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/1097-0215(200002)9999:9999<::AID-IJC1034>3.0.CO;2-S |
| P698 | PubMed publication ID | 11146448 |
| P2093 | author name string | M Yao | |
| Y Nakatani | |||
| H Uemura | |||
| M Yoshida | |||
| M Baba | |||
| S Kaneko | |||
| S Ota | |||
| K Kondo | |||
| K Kobayashi | |||
| M Hosaka | |||
| N Sakai | |||
| T Kishida | |||
| Y Nagashima | |||
| S Kawakami | |||
| P4510 | describes a project that uses | SN12C | Q54955018 |
| VH-Renal | Q54993100 | ||
| VMRC-RCW | Q54993288 | ||
| VMRC-RCZ | Q54993289 | ||
| YCR-1 | Q54995346 | ||
| A-498 | Q54606041 | ||
| ACHN | Q54608371 | ||
| Caki-1 | Q54808374 | ||
| KC12 | Q54899602 | ||
| KWA-RC | Q54900760 | ||
| MTS-RC | Q54907017 | ||
| NSK-RC | Q54931069 | ||
| OUR-10 | Q54936814 | ||
| OUR-20 | Q54936815 | ||
| SGE-RC | Q54953183 | ||
| SMKT-R2 | Q54954962 | ||
| SMKT-R3 | Q54954964 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | renal carcinoma | Q18556333 |
| cell line | Q21014462 | ||
| P304 | page(s) | 219-224 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | International Journal of Cancer | Q332492 |
| P1476 | title | PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines | |
| P478 | volume | 91 |
| Q44714283 | A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells |
| Q40430804 | Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor |
| Q44568144 | Analysis of PTEN gene by fluorescent in situ hybridization in renal cell carcinoma |
| Q36243104 | Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma. |
| Q92200712 | Evaluation of PTEN and CD4+FOXP3+ T cell expressions as diagnostic and predictive factors in endometrial cancer: A case control study |
| Q81228758 | Expression and significance of PTEN and VEGF in canine mammary gland tumours |
| Q73437715 | Expression and significance of new tumor suppressor gene PTEN in primary liver cancer |
| Q79249861 | Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth |
| Q37401031 | Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays |
| Q36178870 | Growth, invasion, metastasis, differentiation, angiogenesis and apoptosis of gastric cancer regulated by expression of PTEN encoding products |
| Q37412363 | Hereditary kidney cancer syndromes |
| Q51721747 | High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer. |
| Q36178164 | Inactivation of PTEN is associated with increased angiogenesis and VEGF overexpression in gastric cancer |
| Q39704965 | Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. |
| Q74099329 | Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis |
| Q53390981 | Loss of tumor suppressor protein PTEN during renal carcinogenesis. |
| Q37993823 | Mammalian target of rapamycin and the kidney. I. The signaling pathway |
| Q38207580 | Metastatic Renal Cancer: What Role for Everolimus? |
| Q89983824 | Modeling clear cell renal cell carcinoma and therapeutic implications |
| Q33729097 | Molecular genetics of clear-cell renal cell carcinoma |
| Q33599713 | Molecular targeted therapy in advanced renal cell carcinoma: A review of its recent past and a glimpse into the near future |
| Q73271272 | Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in advanced gastric carcinomas |
| Q93379768 | Mutations in renal cell carcinoma |
| Q39459220 | NOTCH1 functions as an oncogene by regulating the PTEN/PI3K/AKT pathway in clear cell renal cell carcinoma |
| Q35633427 | Nuclear transport and cancer: from mechanism to intervention |
| Q40662735 | Overexpression of hepatocyte growth factor receptor in renal carcinoma cells indirectly stimulates tumor growth in vivo |
| Q39844741 | PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma |
| Q38921200 | Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma |
| Q35925866 | Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome |
| Q36816038 | Prognostic biomarkers in renal cell carcinoma |
| Q38411398 | RET protein expression in papillary renal cell carcinoma |
| Q35606411 | Specific genomic aberrations predict survival, but low mutation rate in cancer hot spots, in clear cell renal cell carcinoma |
| Q40409431 | Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma |
| Q81086267 | Systemic therapy for renal cell carcinoma |
| Q34116818 | The complexes of mammalian target of rapamycin. |
| Q37086022 | mTOR pathway in renal cell carcinoma |
Search more.